The development of molecularly targeted anticancer agents relies on large panels of tumour-specific preclinical models closely recapitulating the molecular heterogeneity observed in patients. Here we describe the mutational and gene expression analyses of 151 colorectal cancer (CRC) cell lines. We find that the whole spectrum of CRC molecular and transcriptional subtypes, previously defined in patients, is represented in this cell line compendium. Transcriptional outlier analysis identifies RAS/BRAF wild-type cells, resistant to EGFR blockade, functionally and pharmacologically addicted to kinase genes including ALK, FGFR2, NTRK1/2 and RET. The same genes are present as expression outliers in CRC patient samples. Genomic rearrangements (translocations) involving the ALK and NTRK1 genes are associated with the overexpression of the corresponding proteins in CRC specimens. The approach described here can be used to pinpoint CRCs with exquisite dependencies to individual kinases for which clinically approved drugs are already available.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Medico, E;Russo, M;Picco, G;Cancelliere, C;Corti, G;Buscarino, M;Isella, C;Lamba, S;Beccuti, M;Cordero, F;Di Nicolantonio, F
;
Bardelli, A (co-last and corresponding authors)
2015

Abstract

The development of molecularly targeted anticancer agents relies on large panels of tumour-specific preclinical models closely recapitulating the molecular heterogeneity observed in patients. Here we describe the mutational and gene expression analyses of 151 colorectal cancer (CRC) cell lines. We find that the whole spectrum of CRC molecular and transcriptional subtypes, previously defined in patients, is represented in this cell line compendium. Transcriptional outlier analysis identifies RAS/BRAF wild-type cells, resistant to EGFR blockade, functionally and pharmacologically addicted to kinase genes including ALK, FGFR2, NTRK1/2 and RET. The same genes are present as expression outliers in CRC patient samples. Genomic rearrangements (translocations) involving the ALK and NTRK1 genes are associated with the overexpression of the corresponding proteins in CRC specimens. The approach described here can be used to pinpoint CRCs with exquisite dependencies to individual kinases for which clinically approved drugs are already available.
6
7002
1
10
http://www.nature.com/ncomms/2015/150430/ncomms8002/full/ncomms8002.html
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59857
colorectal cancer; EGFR; cetuximab; Tyrosine kinase inhibition
Medico, E; Russo, M; Picco, G; Cancelliere, C; Valtorta, E; Corti, G; Buscarino, M; Isella, C; Lamba, S; Martinoglio, B; Veronese, S; Siena, S; Sartore-Bianchi, A; Beccuti, M; Mottolese, M; Linnebacher, M; Cordero, F; Di Nicolantonio, F*; Bardelli, A*; (*co-last and *corresponding authors)
File in questo prodotto:
File Dimensione Formato  
Medico_CRC_encyclopedia_NatComm_2015_Aperto.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 10.22 MB
Formato Adobe PDF
10.22 MB Adobe PDF Visualizza/Apri
2015_Medico_CRC_encyclopedia_NatComm_Article+SI.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 5.84 MB
Formato Adobe PDF
5.84 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1509370
Citazioni
  • ???jsp.display-item.citation.pmc??? 127
  • Scopus 192
  • ???jsp.display-item.citation.isi??? 190
social impact